Its time to stop the guessing games with your medication
The Endocrine Society's 2023 obesity pharmacotherapy guideline states: "When a patient does not achieve adequate weight loss on a maximally tolerated dose of a GLP-1 receptor agonist, switching to an agent with a broader receptor profile is a reasonable escalation strategy, provided the patient is counseled on the investigational status of newer agents" [5]
Semaglutide injections are placed under the skin and in the fatty tissue
Many patients report noticing increased hunger beginning around day 10 to 14 after their final injection, coinciding with the point when tirzepatide levels drop below therapeutic threshold
Stack L-carnitine with caffeine (200mg pre-workout) and resistance training for maximum fat loss efficiency
The study of nearly 28,000 23AndMe users who reported taking the weight-loss drugs found that a mutation in GLP1R, the gene for the protein targeted by GLP-1 drugs, is modestly but significantly associated with increased efficacy of the medications, researchers reported in Nature